ストックスクリーナーアプリを入手
0.26
10.34%
-0.03
アフターアワーズ：
.27
0.01
+3.85%
Syros Pharmaceuticals Inc (SYRS) 最新ニュース
Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia
Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com India
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros pharmaceuticals chief development officer sells shares for $7,949 By Investing.com - Investing.com UK
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - MSN
Brookline Capital Downgrades Syros Pharmaceuticals (SYRS) - MSN
Syros cut to neutral by H.C. Wainwright on failed drug study - MSN
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes - XM
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - TipRanks
What is HC Wainwright’s Forecast for SYRS Q1 Earnings? - Defense World
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus.com
Blue Owl Capital Holdings LP Increases Stake in Syros Pharmaceuticals Inc - GuruFocus.com
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Neutral Rating from HC Wainwright - Defense World
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
JMP Securities cuts Syros Pharma stock rating following unsuccessful trial By Investing.com - Investing.com Australia
Syros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setback - Investing.com Canada
No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld Online
Syros’s Hopes Dashed As Tamibarotene Flunks Phase III MDS Trial - Citeline News & Insights
Syros Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada
JMP Securities cuts Syros Pharma stock to Market Perform - Investing.com
U.S. Stock market: Syros Pharmaceuticals(−86.21%), GlucoTrack(−77.70%) and others among the most volatile stocks during mid day trading - Business Upturn
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga
Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen - TipRanks
Syros Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com
Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology
U.S. Stock market: Syros Pharmaceuticals surges by 680.00% while Spirit Airlines rises by 184.96% in early trading - Business Upturn
Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge - Fierce Biotech
Syros Pharmaceuticals' (SYRS) Hold Rating Reiterated at Brookline Capital Management - MarketBeat
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $5.00 - MarketBeat
JMP Securities Reiterates Market Perform Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat
Syros Pharmaceuticals' (SYRS) "Hold" Rating Reaffirmed at TD Cowen - MarketBeat
Syros Pharmaceuticals Shares Plummet Premarket After Study Failure - MarketWatch
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default - BioSpace
TD Cowen downgrades Syros Pharma stock to Hold on trial failure - Investing.com
Syros downgraded to Market Perform from Outperform at JMP Securities - TipRanks
Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN
Syros Pharmaceuticals trial fails to meet primary goal - Investing.com
Syros Pharmaceuticals trial fails to meet primary goal By Investing.com - Investing.com UK
Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan
Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat
SYRS (Syros Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com
Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com
SYRSW (Syros Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) - Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results - MarketBeat
Earnings call: Syros Pharmaceuticals outlines tamibarotene progress By Investing.com - Investing.com South Africa
Earnings call: Syros Pharmaceuticals outlines tamibarotene progress - Investing.com India
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
HC Wainwright Reaffirms "Buy" Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlight - GuruFocus.com
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):